Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; balance assessment systems to evaluate patients with balance disorders. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was founded in 1987 and is headquartered in Pleasanton, California.
IPO Year:
Exchange: NASDAQ
Website: natus.com
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
15-12G - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
S-8 POS - NATUS MEDICAL INC (0000878526) (Filer)
POS AM - NATUS MEDICAL INC (0000878526) (Filer)
Fastest customizable press release news feed in the world
SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc
NEW YORK, July 21, 2022 /PRNewswire/ -- Novanta Inc. (NASD: NOVT) will replace Six Flags Entertainment Corp. (NYSE:SIX) in the S&P MidCap 400, and Six Flags will replace Natus Medical Inc. (NASD: NTUS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 26. ArchiMed acquired Natus Medical in a deal that closed today. Six Flags Entertainment is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 26, 2022 S&P MidCap 400 Addition Novanta NOVT Information Technology S&P MidCap 400
MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue
Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22 MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022. For the first quarter ended March 31, 2022, the Company reported revenue of $119.8 million, an increase of 4.2% compared to $114.9 million reported for the fir
Highlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app
PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes
Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47 PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months and full year ended December 31, 2021. For the fo
PLEASANTON, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced preliminary 2021 fourth quarter and full year revenue. The Company expects to report revenue of approximately $127.5 to $128.5 million for the fourth quarter of 2021, and full year 2021 of $472.3 to $473.3 million. "We are pleased with the high single digit revenue growth delivered by our Natus Teammates in the fourth quarter despite supply chain constraints impacting the cost of logistics and
PLEASANTON, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Thomas J. Sullivan, President and Chief Executive Officer, and Drew Davies, Executive Vice President and Chief Financial Officer, will be presenting at the 24th Annual Needham Virtual Growth Conference from 2:00 PM to 2:40 PM ET on Friday, January 14th. In addition, Mr. Sullivan and Mr. Davies will also host one-on-one meetings during the day with institutional investors. Investors interes
PLEASANTON, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 fourth quarter financial results after the close of the market on Thursday, February 24th. Natus management will host a conference call on Friday, February 25th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 f
Live Leadership Updates
SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc
Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth. Earlier this year, the Board of Directors engaged a strategic consulting firm to assist it in developing a strategy to build upon Natus' market leading p
Live finance-specific insights
MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue
Highlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app
PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes
Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47 PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months and full year ended December 31, 2021. For the fo
PLEASANTON, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 fourth quarter financial results after the close of the market on Thursday, February 24th. Natus management will host a conference call on Friday, February 25th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 f
Q3-2021 Key ResultsRevenue (millions)$113.9 • Revenue increased 11% compared to Q3 2020GAAP EPS$0.16 • Generated $7.1 million in operating cash flowNon-GAAP EPS$0.28 PLEASANTON, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and nine months ended September 30, 2021. For the third quarter ended September 30, 2021, the Company reported revenue of $113.9 million, an i
PLEASANTON, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 third quarter financial results after the close of the market on Thursday, November 4th. Natus management will host a conference call on Friday, November 5th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 fo
Q2-2021 Key ResultsRevenue (millions)$116.0 • Revenue increased 37% compared to Q2 2020• Generated $19.4 million in operating cash flow• GAAP and Non-GAAP EPS increased by $0.36 and $0.42, respectively compared to Q2 2020GAAP EPS$0.10 Non-GAAP EPS$0.29 PLEASANTON, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and six months ended June 30, 2021. For the second quarter ended June 30, 2021, the Company reported revenue
This live feed shows all institutional transactions in real time.
SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G - NATUS MEDICAL INC (0000878526) (Subject)